Endocrine Abstracts

IntroductionDysregulation of alternative splicing is emerging as a new hallmark of cancer. This dysregulation may originate from mutations and/or altered expression of specific components of the splicing machinery. Indeed, our group has shown that the expression profile of the splicing machinery is altered in several types of cancer, including endocrine-related cancers. However, to date, the status of alternative splicing and its putative dysregulation h...